IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	Data is not available	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	Data is not available	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	Data is not available	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

Data is not available

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

Data is not available

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

Data is not available

2024/12/30

Summary

According to Frost & Sullivan, we ranked the fourth among all Chinese drama series companies in terms of revenue in 2021. We accounted for approximately 2.5% of the total market share in 2021, amongst the highly fragmented drama series industry in China. We typically create high viewership drama series based on our abundant reserve of original IPs. Since our inception in 2014 in Shanghai, we have been dedicated to the full value chain of operations including investment, production, distribution, promotion, and derivatives licensing of drama series. During the Track Record Period, we generated revenue from three business lines: ‧ Original drama series: We develop IPs, produce and distribute drama series and accordingly we charge licensing fees for the broadcasting rights of our original drama series from domestic online video platforms and TV channels as well as overseas platforms both directly and through third-party distributors; ‧ Content marketing: We provide a suite of content-based marketing services, including product placement and other services to our clients, leveraging our original drama series and proprietary IPs, charging fixed service fees; and ‧ Other businesses: We also provide other services including (i) producing made-to- order drama series based on customer orders; (ii) developing, producing and distributing films; (iii) investing in drama series as a non-executive producer; (iv) licensing our IP derivatives adaptation rights. During the Track Record Period, we also provided artiste management services. We disposed of the relevant subsidiary in 2020 and we ceased providing such service afterwards. Since our inception and up to the Latest Practicable Date, we had produced and distributed a total of 17 drama series. 15 of them are original drama series in which we acted as the lead/sole investor and the executive producer, and we therefore own proprietary rights of these drama series. According to Frost & Sullivan, six of our eight original drama series broadcast from 2019 to 2021 were high viewership drama series, representing a high viewership drama series rate of approximately 75.0%, far exceeding the average high viewership drama series rate of our top five competitors by revenue at approximately 45.9% from 2019 to 2021. In addition, our six high viewership drama series broadcast from 2019 to 2021 garnered a total of more than 16.3 billion view counts on online video platforms during first-run broadcast period and annual viewership rate of over 1.0% on TV channels during the same period. Our day-to-day life themed drama series such as “A Love for Separation” (小別離), “A Little Reunion” (小歡喜), “A Little Dilemma” (小舍得), “Nothing but Thirty” (三十而已) and “Twenty Your Life On” (二十不惑) focus on popular contemporary topics such as family life, education, and female empowerment, delivering positive value propositions and inspiring extensive discussion. We pride ourselves in taking the lead in the development of premium original IP in-house and have built an abundant reserve of original IPs and strong pipeline, allowing us to possess a competitive edge over many of our competitors. Among the ten drama series we have finished production from 2019 to 2021, eight of them are original drama series, representing a ratio of 80.0%. The ratio ranked the second among the top five producers in the industry from 2019 to 2021, according to Frost & Sullivan. Furthermore, we are committed to our diversified growth strategies. We continue to explore new growth avenues such as content marketing, derivative licensing and overseas distribution, in order to maximize the commercial value of our proprietary IP rights and reinforce our leadership in the industry. Source: Linmon Media (09857) Prospectus (IPO Date : 2022/07/29)
Listing Market	MAIN
Industry	Movies & Entertainment
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Su Xiao (19.72%) [00700] Tencent Holdings Limited (18.94%) Shanghai Hongni Enterprise Management Partnership (15.46%) Chen Fei (9.15%) Xu Xiao Ou (9.15%) Zhou Yuan (6.27%)
Directors	Su Xiao (Chairman and President and Executive Director) Xu Xiao Ou (Vice President and Executive Director) Zhou Yuan (Vice President and Executive Director) Chen Fei (Chief Executive Officer and Executive Director) Sun Zhonghuai (Non-Executive Director) Zhang Rong (Non-Executive Director) Jiang Changjian (Independent Non-Executive Director) Long Yu (Independent Non-Executive Director) Tang Songlian (Independent Non-Executive Director)
Company Secretary	Li Zhen Ng Ka Man
Principal Bankers	China Merchants Bank China Minsheng Banking Corp. Ltd. China CITIC Bank Corporation Limited
Solicitors	Clifford Chance
Auditors	Moore CPA Limited
Registered Office	31st Floor, Tower Two, Times Square 1 Matheson Street, Causeway Bay, Hong Kong
Share Registrars	Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No	(852) 2980-1333
Internet Address	http://www.linmon.cn
Email Address
Tel No	(86 10) 5370-8900
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates